Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study.

Nina StojchevaStacy GladmanMarianne SoergelChristof ZittRoxana DrakeTony LockettCarine MarchandPierre FustierVaia StavropoulouElena FernandezNathana Lopes PettigianiKate WatkinsAdeep PuriRandall WatsonPhilippe LegenneMichael StumppMalcolm Boyce

Published in: British journal of clinical pharmacology (2023)

Ensovibep proved safe in this first-in-human safety study and exhibited pharmacokinetic and pharmacodynamic parameters consistent with the expected treatment period required for acute COVID-19 infection.

Keyphrases

endothelial cells
sars cov
induced pluripotent stem cells
pluripotent stem cells
open label
liver failure
randomized controlled trial
aortic dissection
clinical trial
respiratory failure
combination therapy
study protocol
extracorporeal membrane oxygenation
drug induced